Metastat (OTCMKTS:MTST) & Evolus (NASDAQ:EOLS) Critical Analysis

Metastat (OTCMKTS:MTST) and Evolus (NASDAQ:EOLS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Risk and Volatility

Metastat has a beta of 295.91, suggesting that its stock price is 29,491% more volatile than the S&P 500. Comparatively, Evolus has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.

Earnings & Valuation

This table compares Metastat and Evolus”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metastat	N/A	N/A	N/A	N/A	N/A
Evolus	$297.18 million	0.93	-$51.64 million	($0.81)	-5.27

Metastat has higher earnings, but lower revenue than Evolus.

Insider and Institutional Ownership

90.7% of Evolus shares are held by institutional investors. 8.5% of Metastat shares are held by insiders. Comparatively, 5.9% of Evolus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Metastat and Evolus, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metastat	0	0	0	0	0.00
Evolus	1	1	4	0	2.50

Evolus has a consensus target price of $16.00, suggesting a potential upside of 274.71%. Given Evolus’ stronger consensus rating and higher probable upside, analysts plainly believe Evolus is more favorable than Metastat.

Profitability

This table compares Metastat and Evolus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Metastat	N/A	N/A	N/A
Evolus	-17.38%	N/A	-21.57%

Summary

Evolus beats Metastat on 5 of the 9 factors compared between the two stocks.

About Metastat

MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care; MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment ion sites; and prognostic diagnostic to predict risk of cancer metastasis. The company’s therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat, Inc. is based in Boston, Massachusetts.

About Evolus

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.